



Pain in Dupuytren's disease

Leen VANDECASTEELE, Ilse DEGREEF

From the KU Leuven, Belgium

To investigate pain in patients with Dupuytren disease, we analyzed the literature on pre- and post-interventional pain and complex regional pain syndrome. The pre-interventional pain intensity score of primary Dupuytren ranged from 0.3/10 to 2.0/10. One year after surgery or needle fasciotomy, no significant change of pain could be found. Collagenase therapy significantly reduced the mean pain intensity score from 1.3/10 [SD 2.2] to 0.5/10 [1.5] ($p < 0.01$) after one year. The prevalence of complex regional pain syndrome after fasciectomy ranged from 0% to 12.8%, after needle fasciotomy from 0% to 6.3%, and after collagenase therapy from 0% to 3.0%. We conclude that for most Dupuytren patients, pain is not an issue. A minority seems to suffer pain and collagenase treatment appears to reduce this complaint significantly. However, complex regional pain syndrome is a known complication of Dupuytren treatment, with a low incidence after minimal invasive treatment.

Keywords : Dupuytren ; pain ; CRPS ; collagenase ; surgery ; needle aponeurotomy ; amputation ; splinting.

INTRODUCTION

Dupuytren disease (DD) is very common in Northern Europe with a 21% prevalence at the age of 65 (50). Nowadays, no curative treatment is known. The indication for a symptomatic therapy is largely based on the degree of flexion contracture and functional impairment. As a consequence, the

literature focuses on goniometric outcomes. Long-term pain is less studied.

If DD causes pre-interventional pain, patients hope that this pain may improve with a symptomatic treatment for Dupuytren contractures. However, chronic pain and complex regional pain syndrome (CRPS) can be a complication of Dupuytren treatment itself.

The aim of this literature review was to analyze reports on long-term pain and complex regional pain syndrome before and after treatment of DD. This information is important for patients who consider treatment for Dupuytren contracture.

MATERIALS AND METHODS

A search was performed on Pubmed, Web of Science, Cochrane library and Embase starting from the inception of the databases until November 2018 with the search terms Dupuytren contracture, pain, CRPS and synonyms, outcome, one year results and all the different treatment options. We

-
- Leen Vandecasteele¹,
 - Ilse Degreef², MD, PhD, Orthopaedic Surgeon

¹KU Leuven, Belgium.

²Department of Orthopaedic Surgery, University Hospitals Leuven, Belgium.

Correspondence : Leen Vandecasteele, KU Leuven, Belgium.

E-mail : leen.vandecasteele@student.kuleuven.be ; ilse.degreef@uzleuven.be

© 2020, Acta Orthopædica Belgica.

considered articles written in English, German, Dutch or French, and excluded other languages, case reports, retracted articles and studies with other factors, e.g. simultaneous carpal tunnel syndrome and Dupuytren's disease. We included articles that reported 1) a pain intensity score or prevalence of pain of patients with DD before treatment and/or 2) prevalence of pain/CRPS or pain intensity scores of patients with DD at least 3 weeks after treatment. We converted the pain intensity scores to a scale from zero to ten.

RESULTS

We included 89 articles. The pre-interventional pain intensity score ranged from 0/10 to 3.3/10 (24,47,48,59,60,69,76,77) for all DD patients, for primary DD patients these score ranged from 0.3/10 to 2.0/10 (24,47). Hurst L.C. et al. (44) observed pain as the first sign of DD in 2.3% of the cases. Spies C.K. et al. (76,77) reported that 13% of the patients with primary and recurrent disease had pain, pre-interventionally, and 44% of the patients with recurrent DD.

In table I, the reported pain intensity scores after surgery and needle fasciotomy are listed. Overall, no significant differences were found between the

groups. The pain intensity scores one year after surgery ranged from 0/10 to 3.3/10.

One year after collagenase (CCH) therapy, Odinson A. et al. (59) found a significant decrease of the mean pain intensity score from 1.3/10 [SD 22] pre-interventionally to 0.5/10 [15] ($p < 0.01$). Scherman A. et al. (71) reported a mean pain intensity score of 0.4/10 and 5.3% of the patients complained of pain one year after CCH. Other authors (5,15,22,23) reported that their patients were pain free after four weeks to one year. Bear B.J. et al. (11) observed 1 patient with persistent pain that resolved within 6 months. Vollbach F.H. et al. (86), mentioned that 71% of the patients experienced temporary pain when grasping objects at 1 month. Overall, little chronic pain was reported after CCH treatment.

Amputation and arthrodesis of fourth or fifth digit are sometimes chosen as salvage procedure in severe and/or recurrent Dupuytren disease. Degreef I (25) et al. reported a median pain intensity score of 1.75/10, 1 to 6 years after amputation and 50% of the patients experienced pain. Jensen C.M. et al. (45) observed neuroma in 22% and phantom pain in 17% 4 years after finger amputation. Honecker S. et al. (42) presented shortening arthrodesis by resection of the proximal interphalangeal joint as alternative

Table I. — Surgery and needle fasciotomy

	Study type	n (patients)	Treatment	Pre-interventional pain intensity score : Median/mean (0-10) [SD]	Post-interventional pain intensity score : Median/mean (0-10) [SD]	Time after treatment
Ganeval A. et al. (36)	Prospective cohort	20	Digital needle fasciotomy	-/-	1/1.8	10 m (range 3-24 m)
Spies C.K. et al. (77)	Retrospective cohort	15	Percutaneous needle fasciotomy	2/15 (13.3%)	-/-	40 m
Scherman P. et al. (71)	RCT	45	Percutaneous needle fasciotomy + sometimes night splint	-/-	0/0.1	12 m
Kemler M.A. (48)	Pilot study (RCT)	26	Limited fasciectomy + primary closure	-/0 [0]	-/0.7 [1.3]	12 m
		28	Limited fasciectomy + primary closure + splinting	-/0 [0]	-/1.3 [2.0]	
Pearl R.A. et al. (60)	Prospective cohort study	51	Not specified	3.3 /-	3.3 /-	8 m
Rodrigues J. et al. (69)	Cross-sectional study	750	Fasciectomy or dermofasciectomy or percutaneous needle fasciotomy	2.5 /-	0 /-	1 y
					0 /-	
Note : pain in arm, shoulder and hand						

Table II. — Post-interventional pain

	% of patients with pain	post-interventional time
Limited fasciectomy + primary closure (1,53,54,76,86,91)	0-27%	4 m-20 y
Limited fasciectomy + open palm technique (53)	0%	
Fasciectomy + external fixation (12)	7.7%	
Amputation (25)	50%	9 m-81 m
Arthrodesis (42,58)	25%-83.2%	
Combinations of surgical techniques (41)	4%	>3 w
Percutaneous needle fasciotomy (36,71,77)	0-55%	3 m-24 m
CCH (5,11,15,22,23,71)	0-5%	2 w-12 m
Topical injections of hydrocortisone acetate (89)	9%	2 m-24 m

Table III. — CRPS

Treatment	CRPS (%)
Fasciectomy	
Limited fasciectomy + open palm technique (33,34,37,53,70,73,74)	0%-9.3%
Limited fasciectomy + primary skin closure (16,21,37,47,53,55,65,66,76,80,82,91,92)	0%-9.2%
Complete fasciectomy + primary skin closure (85)	1.8%
Segmental aponeurectomy (20)	0%
Fasciectomy + external fixation (18)	38.5%
Fasciectomy (type not further specified or combination) + primary skin closure (4,14,19,26,28,46,49,83,87,88)	0%-12.8%
Dermatofasciectomy/fasciectomy + skin graft/flap (2,74,83,87)	0%-5%
Combinations of surgical techniques (29,30,31,39,40,67,81)	0%-12.8%
Fasciotomy	
Percutaneous needle fasciotomy (9,13,35,36,56,64,65,66,75,79)	0%-6.3%
Percutaneous aponeurotomy and lipofilling (43,47)	4.4%-5%
Subcutaneous fasciotomy (68)	0%
CCH (6,7,8,10,23,27,51,57,59,61,62,63,75,79,84)	0%-3.0%
Sex	
women + all types of surgery (3,32,33,34,72,78)	0.9%-50%
men + all types of surgery (3,32,33,90)	1.5%-12.5%
Primary versus recurrent	
primary + all types of treatment (26,38,46,47,65,74,83)	0-6.3%
recurrent + all types of treatment (76)	0%

to amputation of the fifth ray. The median pre-operative pain intensity score dropped from 5/10 and 75% of the patients with pain to a median pain intensity score of zero and 25% of the patients with pain after 9-81 months. Novoa-Parra C.D. et al. (58)

presented PIP joint arthrodesis with interlocking screw in severe DD recurrence. A hundred percent of the patients reported pre-interventional pain, but the median pain intensity score did not improve significantly, from 4/10 pre-intervention to 1.5/10

one year after the arthrodesis, pain persisted in 83.3%. In general, arthrodesis lowered the pain but the scores remained high.

Zachariae L. et al. (89), reported in 1955 that the percentage of patients who experienced pain in DD dropped from 36% to 9% 2 months to 2 years after injecting hydrocortisone acetate.

von Campe A. et al. (17) observed patients that underwent surgery for persistent pain due to DD. The mean pain intensity score dropped from 4.9/10 to 0/10 25 months after fasciectomy, however, 2 of the 10 patients developed CRPS.

Table II summarizes the percentages of patients with post-interventional pain. The percentages were the lowest after collagenase, the highest after amputation and arthrodesis.

Table III summarizes the percentages of patients with CRPS. The studies that compared the prevalence of CRPS between the sexes (3,32,33,90) all reported a higher percentage of CRPS in women, with the exception of Anwar M.U. et al. (3), who reported a percentage of CRPS of 2% for men, versus 0.8% for women. The percentage of CRPS in women was significantly higher in the study by Sennwald G.R. et al. (72) ($p < 0.02$).

Zemel N.P. et al. (90) reported on long term outcome of Dupuytren surgery in women in 1987. He performed an extensive fasciectomy and a simultaneous carpal tunnel release in 12 women without the presence of carpal tunnel syndrome. CRPS developed in 58% (7 of 12) of these hands, versus 8% (5 of 61 hands) of the hands without carpal tunnel release. This was statistically significant. Furthermore, 46% of the hands that underwent a more extensive fasciectomy, developed CRPS, versus 10% of the hands who received a limited fasciectomy. This was also significant.

DISCUSSION

Pre-interventional pain intensity scores of primary Dupuytren ranged from 0.3 to 2.0/10. One year after surgery or needle fasciotomy, no significant change in pain reporting could be found. However, collagenase therapy significantly reduced the pain after 1 year. The prevalence of CRPS after fasciectomy ranged from 0% to 12.8%, after needle

fasciotomy from 0% to 6.3%, and after collagenase therapy from 0% to 3.0%.

This review has several weaknesses, i.e. little statistical evidence in the studies, the diversity of the patient groups, and the fact that, throughout the years, no clear definitions of CRPS and lots of synonyms were used. Moreover, we only focused on pain and not on other outcomes. This review's strength is however its specific focus on pain in DD, which is rarely highlighted in treatment outcome reports.

The treatment of primary pain in DD is challenging. The role of surgery is unclear. Recently, von Campe A. et al. (17) performed fasciectomy for painful DD and suggested that the indication for surgery in DD should even be extended to the presence of painful nodules for over 1 year. They suggested a histological inspection on a large scale to investigate whether histological changes are linked to pain in DD. However, surgery for DD may also induce pain.

Another promising option for persistent pain in DD seemed to be CCH therapy. As stated in the results, Odinson A. et al. (59) reported significantly less pain after 1 year and Costas B. et al. (24) found that CCH therapy improved nodular pain. However, it is possible that less severe cases of Dupuytren were treated by CCH therapy. This might bias our results compared to the surgery groups.

Furthermore, Jensen C.M. et al. (45) reported amputation as a treatment of pain due to nerve lesions of previous operations. In general, amputation of the fourth and especially the fifth finger is frequently complicated with neuromata after more proximal amputations. Therefore, amputation should be limited to a selected group of patients. Honecker S. et al. (42) presented arthrodesis as an alternative to amputation, with the advantage that nerves are preserved, and consequently, less neuroma's and pain are present. However, in this review, we did not find a difference between the prevalence of pain after amputation versus after arthrodesis.

A common cause of pain after Dupuytren treatment is CRPS with an incidence of 0 to 12.8% after fasciectomy, but it is difficult to predict. Possibly preoperative pain could indicate a higher susceptibility. We did not find any reports that stated

that patients who suffered from pre-interventional pain had a higher chance of developing CRPS. However, von Campe A. et al. (17) reported an incidence of 20% in patients undergoing fasciectomy for pain, which is higher than the overall incidence after surgery. The role of simultaneous carpal tunnel decompression is unclear since Zemel et al. (90) found significantly more instances of CRPS and Lilly S.I. et al. (52) reported that only 3% of the simultaneous group developed CRPS.

CONCLUSION

DD is a highly prevalent disease, but pain is rather rare and mostly mild if left untreated. The effect of surgery on pain is unclear, although CCH was reported to significantly decrease pain. Preoperative pain may indicate a higher risk for CRPS after treatment, which is more likely after more invasive surgery. We suggest that future studies on treatment outcome in DD include pain in their results.

Acknowledgement

We would like to thank dr. Rodrigues J. from the Nuffield Department and dr. Selles R.W from the Erasmus Medical Center for the extra data on their articles (47,69).

REFERENCES

1. Abe Y, Rokkaku T, Ofuchi S, et al. Surgery for Dupuytren's Disease in Japanese Patients and a new Preoperative Classification. *J Hand Surg Br Eur Vol* 2004 ; 29B : 233-237.
2. Ali SN, McMurtrie A, Rayatt S, et al. Ulnar-based skin flap for Dupuytren's fasciectomy. *Scand J Plast Reconstr Surg Hand Surg* 2006 ; 40 : 307-310.
3. Anwar MU, Al Ghazal SK, Boome RS. Results of Surgical Treatment of Dupuytren's Disease in Women: A Review of 109 Consecutive Patients. *J Hand Surg Am* 2007 ; 32A : 1423-1428.
4. Aparid T, Saint-Cast Y. La plastie de Malingue dans les rétractions digitales de la maladie de Dupuytren: principe, modélisation et application clinique. *Chir Main* 2011 ; 30 : 31-34.
5. Atroshi I, Nordenskjöld J, Lauritzson A, et al. Collagenase treatment of Dupuytren's contracture using a modified injection method. *Acta Orthop* 2015 ; 86 : 310-315.
6. Badalamente MA, Hurst LC. Efficacy and Safety of Injectable Mixed Collagenase Subtypes in the Treatment of Dupuytren's Contracture. *J Hand Surg Am* 2007 ; 32 : 767-774.
7. Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytren's disease. *J Hand Surg Am* 2000 ; 25 : 629-636.
8. Badalamente MA, Hurst LC, Benhaim P, et al. Efficacy and safety of collagenase clostridium histolyticum in the treatment of proximal interphalangeal joints in Dupuytren contracture: Combined analysis of 4 Phase 3 clinical trials. *J Hand Surg Am* 2015 ; 40 : 975-983.
9. Badois FJ, Lermusiaux JL, Massé C, et al. Traitement non chirurgical de la maladie de Dupuytren par aponévrotomie à l'aiguille. *Rev Du Rhum Ed Français* 1993 ; 60 : 808-813.
10. Bainbridge C, Gerber RA, Szczypa PP, et al. Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren's contracture. *J Plast Surg Hand Surg* 2012 ; 46 : 177-183.
11. Bear BJ, Peimer CA, Kaplan FTD, et al. Treatment of Recurrent Dupuytren Contracture in Joints Previously Effectively Treated With Collagenase Clostridium histolyticum. *J Hand Surg Am* 2017 ; 42 : 391.e1-391.e8.
12. Beard AJ, Trail IA. The 's' Quattro in severe dupuytren's contracture. *J Hand Surg Br Eur Vol* 1996 ; 21B : 795-796.
13. Beaudreuil J, Lermusiaux JL, Teysseidou JP, et al. Multi-needle aponeurotomy for advanced Dupuytren's disease: Preliminary results of safety and efficacy (MNA 1 Study). *Jt Bone Spine* 2011 ; 78 : 625-628.
14. Beyermann K, Prommersberger KJ, Jacobs C, et al. Severe contracture of the proximal interphalangeal joint in Dupuytren's disease: Does capsuloligamentous release improve outcome? *J Hand Surg Am* 2004 ; 29 B : 240-243.
15. Binter A, Neuwirth M, Rab M. Behandlung der Dupuytren'schen Kontraktur mit Kollagenase - Ein-Jahres-Follow-up-Analyse anhand von 37 Patienten. *Handchirurgie Mikrochirurgie Plast Chir* 2015 ; 46 : 355-360.
16. Bulstrode NW, Jemec B, Smith PJ. The complications of Dupuytren's contracture surgery. *J Hand Surg Am* 2005 ; 30 : 1021-1025.
17. von Campe A, Mende K, Omaren H, et al. Painful nodules and cords in Dupuytren disease. *J Hand Surg Am* 2012 ; 37A : 1313-1318.
18. Citron N, Messina J. The use of skeletal traction in the treatment of severe primary Dupuytren's disease. *J Bone Jt Surg Br* 1998 ; 80 : 126-129.
19. Citron ND, Nunez V. Recurrence after surgery for Dupuytren's disease: A randomized trial of two skin incisions. *J Hand Surg Am* 2005 ; 30 : 563-566.
20. Clibbon JJ, Logan AM. Palmar segmental aponeurectomy for Dupuytren's disease with metacarpophalangeal flexion contracture. *J Hand Surg Am* 2001 ; 26 B : 360-361.
21. Coert JH, Nérin JPB, Meek MF. Results of partial fasciectomy for Dupuytren disease in 261 consecutive patients. *Ann Plast Surg* 2006 ; 57 : 13-17.
22. Coleman S, Gilpin D, Kaplan FTD, et al. Efficacy and safety of concurrent collagenase clostridium histolyticum

- injections for multiple dupuytren contractures. *J Hand Surg Am* 2014 ; 39 : 57-64.
23. **Coleman S, Gilpin D, Tursi J, et al.** Multiple concurrent collagenase clostridium histolyticum injections to dupuytren's cords: An exploratory study. *BMC Musculoskeletal Disord* 2012 ; 13 : 1-8.
 24. **Costas B, Coleman S, Kaufman G, et al.** Efficacy and safety of collagenase clostridium histolyticum for Dupuytren disease nodules: A randomized controlled trial. *BMC Musculoskeletal Disord* 2017 ; 18 : 1-10.
 25. **Degreef I, De Smet L.** Dupuytren's disease : A predominant reason for elective finger amputation in adults. *Acta Chir Belg* 2009 ; 109 : 494-497.
 26. **Donaldson OW, Pearson D, Reynolds R, et al.** The association between intraoperative correction of Dupuytren's disease and residual postoperative contracture. *J Hand Surg Eur Vol* 2010 ; 35 : 220-223.
 27. **Dreise MM, Stenekes MW, Werker PMN.** Collagenase Treatment for Dupuytren Disease of the Thumb and First Web. *J Hand Surg Am* 2016 ; 41 : 348-353.
 28. **Eberlin KR, Kobraci EM, Nyame TT, et al.** Salvage Palmar Fasciectomy after Initial Treatment with Collagenase Clostridium Histolyticum. *Plast Reconstr Surg* 2015 ; 135 : 1000e-1006e.
 29. **Ebskov LB, Boeckstyns MEH, Sørensen AI, et al.** Day care surgery for advanced dupuytren's contracture. *J Hand Surg Br Eur Vol* 1997 ; 22 : 191-192.
 30. **Edmunds I, Chien C.** A new surgical approach to Dupuytren's disease. *J Hand Surg Eur Vol* 2011 ; 36 : 485-489.
 31. **Engstrand C, Krevers B, Nylander G, et al.** Hand function and quality of life before and after fasciectomy for dupuytren contracture. *J Hand Surg Am* 2014 ; 39 : 1333-1343.e2.
 32. **Ferry N, Lasserre G, Pauchot J, et al.** Particularités de la maladie de Dupuytren chez la femme. À propos de 67 cas. *Ann Chir Plast Esthet* 2013 ; 58 : 663-669.
 33. **Foucher G, Cornil C, Lenoble E, et al.** A modified open palm technique for Dupuytren's disease. *Int Orthop* 1995 ; 19 : 285-8.
 34. **Foucher G, Cornil C, Lenoble E.** Open palm technique for Dupuytren's disease. Postoperative complications results after more than 5 years. *Chirurgie* 1992 ; 118 : 189-196.
 35. **Foucher G, Medina J.** Percutaneous needle aponeurotomy: Complications and results. *Chir Main* 2001 ; 20 : 206-211.
 36. **Ganeval A, Blancher MC, Gouzou S, et al.** L'aponévrotomie digitale à l'aiguille dans la maladie de Dupuytren entraîne-t-elle des lésions des nerfs collatéraux? A propos d'une série de 25 doigts. *Ann Chir Plast Esthet* 2010 ; 55 : 35-41.
 37. **Gelberman RH, Panagis JS, Hergenroeder P, et al.** Wound complications in the surgical management of Dupuytren's contracture: a comparison of operative incisions. *Br Soc Surg Hand* 1982 ; 14 : 248-254.
 38. **Van Giffen N, Degreef I, De Smet L.** Dupuytren's disease : Outcome of the proximal interphalangeal joint in isolated fifth ray involvement. *Acta Orthop Belg* 2006 ; 72 : 671-677.
 39. **Goubier JN, Le Bellec Y, Cottias P, et al.** L'atteinte isolée du cinquième rayon dans la maladie de Dupuytren. *Chir Main* 2001 ; 20 : 212-217.
 40. **Gschwind C, Fricker R, Lacher G, et al.** Does perioperative guanethidine prevent reflex sympathetic dystrophy? *J Hand Surg Am* 1995 ; 20 : 773-775.
 41. **Herweijer H, Dijkstra PU, Nicolai JPA, et al.** Postoperative hand therapy in Dupuytren's disease. *Disabil Rehabil* 2007 ; 29 : 1736-1741.
 42. **Honecker S, Hidalgo Diaz JJ, Naito K, et al.** Proximal interphalangeal arthrodesis of the little finger: A series of 7 cases. *Hand Surg Rehabil* 2016 ; 35 : 262-265.
 43. **Hovius SER, Kan HJ, Smit X, et al.** Extensive percutaneous aponeurotomy and lipografting: A new treatment for dupuytren disease. *Plast Reconstr Surg* 2011 ; 128 : 221-228.
 44. **Hurst LC, Badalamente MA, Hentz VR, et al.** Injectable Collagenase Clostridium Histolyticum for Dupuytren's Contracture. *N Engl J Med* 2009 ; 361 : 968-979.
 45. **Jensen CM, Haugegaard M.** Amputations in the treatment of Dupuytren's disease. *J Hand Surg Am* 1993 ; 18 B : 781-782.
 46. **Johnston P, Larson D, Clark IM, et al.** Metalloproteinase Gene Expression Correlates With Clinical Outcome in Dupuytren's Disease. *J Hand Surg Am* 2008 ; 33 : 1160-1167.
 47. **Kan HJ, Selles RW, Van Nieuwenhoven CA, et al.** Percutaneous Aponeurotomy and Lipofilling (PALF) versus Limited Fasciectomy in Patients with Primary Dupuytren's Contracture: A Prospective, Randomized, Controlled Trial. *Plast Reconstr Surg* 2016 ; 137 : 1800-1812.
 48. **Kemler MA, Hout P, Van Der Horst CMAM.** A pilot study assessing the effectiveness of postoperative splinting after limited fasciectomy for Dupuytren's disease. *J Hand Surg Eur Vol* 2012 ; 37 : 733-737.
 49. **Kjeldal I, Nygaard HP.** Out-patient surgery for Dupuytren's disease under intravenous regional anaesthesia. *J Hand Surg Am* 1988 ; 13 : 257-258.
 50. **Lanting R, Broekstra DC, Werker PMN, et al.** A Systematic Review and Meta-Analysis on the Prevalence of Dupuytren Disease in the General Population of Western Countries. *Plast Reconstr Surg* 2014 ; 133 : 593-603.
 51. **Leclère FM, Mathys L, Vögelin E.** Traitement de la maladie de dupuytren par collagénase injectable, évaluation de l'échographie assistée. *Chir Main* 2014 ; 33 : 196-203.
 52. **Lilly SI, Stern PJ.** Simultaneous Carpal Tunnel Release and Dupuytren's Fasciectomy. *J Hand Surg Am* 2010 ; 35 : 754-759.
 53. **Lubahn JD, Lister GD, Wolfe T.** Fasciectomy and Dupuytren's disease: A comparison between the open-palm technique and wound closure. *J Hand Surg Am* 1984 ; 9 : 53-58.
 54. **Mäkelä EA, Jaroma H, Harju A, et al.** Dupuytren's contracture: The long-term results after day surgery. *J Hand Surg Br Eur Vol* 1991 : 272-274.

55. **Mavrogenis AF, Spyridonos SG, Ignatiadis IA, et al.** Partial fasciectomy for Dupuytren's contractures. *J Surg Orthop Adv* 2009 ; 18 : 106-10.
56. **Medjoub K, Jawad A.** The use of multiple needle fasciotomy in dupuytren disease: Retrospective observational study of outcome and patient satisfaction. *Ann Plast Surg* 2014 ; 72 : 417-422.
57. **Murphy A, Lalonde DH, Eaton C, et al.** Minimally invasive options in dupuytren's contracture: Aponeurotomy, enzymes, stretching, and fat grafting. *Plast Reconstr Surg* 2014 ; 134 : 822e-829e.
58. **Novoa-Parra CD, Montaner-Alonso D, Pérez-Correa JI, et al.** Arthrodesis of the proximal interphalangeal joint of the 4 th and 5 th finger using an interlocking screw device to treat severe recurrence of Dupuytren's disease. *Rev Esp Cir Ortop Traumatol* 2018 ; 62 : 216-221.
59. **Odinsson A, Brenne LE, Lurie TB, et al.** Dupuytren's Contracture. The Safety and Efficacy of Collagenase Treatment. *J Hand Surg Asian-Pacific Vol* 2016 ; 21 : 187-192.
60. **Pearl RA, Belcher HJCR.** Three-dimensional assessment of hand outcome. *Ann R Coll Surg Engl* 2013 ; 95 : 421-426.
61. **Peimer CA, Blazar P, Coleman S, et al.** Dupuytren Contracture Recurrence Following Treatment With Collagenase Clostridium Histolyticum (CORDLESS [Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study]): 5-Year Data. *J Hand Surg Am* 2015 ; 40 : 1597-1605.
62. **Peimer CA, McGoldrick CA, Kaufman G.** Nonsurgical Treatment of Dupuytren Contracture: 3-Year Safety Results Using Collagenase Clostridium histolyticum. *J Hand Surg Am* 2013 ; 38 : e52.
63. **Peimer CA, Skodny P, Mackowiak JI.** Collagenase clostridium histolyticum for dupuytren contracture: Patterns of use and effectiveness in clinical practice. *J Hand Surg Am* 2013 ; 38 : 2370-2376.
64. **Pess GM, Pess RM, Pess RA.** Results of needle aponeurotomy for dupuytren contracture in over 1,000 fingers. *J Hand Surg Am* 2012 ; 37 : 651-656.
65. **Ribak S, Borkowski R, do Amaral RP, et al.** Dupuytren contracture: comparative study between partial fasciectomy and percutaneous fasciectomy. *Rev Bras Ortop (English Ed)* 2013 ; 48 : 545-553.
66. **van Rijssen AL, Gerbrandy FSJ, Linden H Ter, et al.** A Comparison of the Direct Outcomes of Percutaneous Needle Fasciotomy and Limited Fasciectomy for Dupuytren's Disease: A 6-Week Follow-Up Study. *J Hand Surg Am* 2006 ; 31 : 717-725.
67. **Robins RHC, Scott TD, Griffiths DPG.** Day care surgery for dupuytren's contracture. *J Hand Surg Br Eur Vol* 1993 ; 18B : 494-498.
68. **Rodrigo JJ, Niebauer JJ, Brown RL, et al.** Treatment of Dupuytren's contracture. Long-term results after fasciotomy and fascial excision. *J Bone Joint Surg Am* 1976 ; 58 : 380-387.
69. **Rodrigues JN, Zhang W, Scammell B, et al.** Validity of the Disabilities of the Arm, Shoulder and Hand patient-reported outcome measure (DASH) and the Quickdash when used in Dupuytren's disease. *J Hand Surg Eur Vol* 2016 ; 41 : 589-599.
70. **Roulet S, Bacle G, Guéry B, et al.** Outcomes at 7 and 21 years after surgical treatment of Dupuytren's disease by fasciectomy and open-palm technique. *Hand Surg Rehabil* 2018 ; 37 : 305-310.
71. **Scherman P, Jenmalm P, Dahlin LB.** One-year results of needle fasciotomy and collagenase injection in treatment of Dupuytren's contracture: A two-centre prospective randomized clinical trial. *J Hand Surg Eur Vol* 2016 ; 41 : 577-582.
72. **Sennwald GR.** Fasciectomy for treatment of Dupuytren's disease and early complications. *J Hand Surg Am* 1990 ; 15 : 755-761.
73. **Shaw DL, Wise DI, Holms W.** Dupuytren's disease treated by palmar fasciectomy and an open palm technique. *J Hand Surg Br Eur Vol* 1996 ; 21B : 484-485.
74. **Skoff HD.** The surgical treatment of Dupuytren's contracture: A synthesis of techniques. *Plast Reconstr Surg* 2004 ; 113 : 540-544.
75. **Skov ST, Bisgaard T, Søndergaard P, et al.** Injectable Collagenase Versus Percutaneous Needle Fasciotomy for Dupuytren Contracture in Proximal Interphalangeal Joints: A Randomized Controlled Trial. *J Hand Surg Am* 2017 ; 42 : 321-328.e3.
76. **Spies CK, Hahn P, Müller LP, et al.** The efficacy of open partial aponeurotomy for recurrent Dupuytren's contracture. *Arch Orthop Trauma* 2016 ; 136 : 881-889.
77. **Spies CK, Müller LP, Skouras E, et al.** Die perkutane Nadelaponeurotomie der Dupuytren-Kontraktur. *Oper Orthop Traumatol* 2016 ; 28 : 12-19.
78. **Stahl S, Calif E.** Dupuytren's Palmar contracture in women. *Isr Med Assoc J* 2008 ; 10 : 445-447.
79. **Strömberg J, Ibsen-Sørensen A, Fridén J.** Comparison of Treatment Outcome After Collagenase and Needle Fasciotomy for Dupuytren Contracture: A Randomized, Single-Blinded, Clinical Trial With a 1-Year Follow-Up. *J Hand Surg Am* 2016 ; 41 : 873-880.
80. **Tay TKW, Tien H, Lim EYL.** Comparison between Collagenase Injection and Partial Fasciectomy in the Treatment of Dupuytren's Contracture. *Hand Surg* 2015 ; 20 : 386-390.
81. **Tripoli M, Merle M.** The "Jacobsen Flap" for the Treatment of Stages III - IV Dupuytren ' S Disease : a Review of 98 Cases. *J Hand Surg Eur Vol* 2008 ; 33E : 779-782.
82. **Uemura T, Kazuki K, Egi T, et al.** Clinical outcomes of primary skin closure with Y-V and Z-plasties for Dupuytren's contracture: Use of one-stage skin closure. *J Plast Surg Hand Surg* 2010 ; 44 : 306-310.
83. **Ullah AS, Dias JJ, Bhowal B.** Does a 'firebreak' full-thickness skin graft prevent recurrence after surgery for Dupuytren's contracture? *J Bone Joint Surg Br* 2009 ; 91 : 374-378.

84. **Verstreken F, Degreeef I, Decramer A, et al.** Effectiveness and safety of collagenase *Clostridium histolyticum* in Dupuytren's disease: An observational study in Belgium. *Acta Orthop Belg* 2016 ; 82 : 405-411.
85. **Vigroux JP, Valentin P.** A natural history of Dupuytren's contracture treated by surgical fasciectomy : the influence of diathesis (76 hands reviewed at more than 10 years). *Ann Chir La Main* 1992 ; 11 : 367-374.
86. **Vollbach FH, Walle L, Fansa H.** Morbus Dupuytren - Patientenzufriedenheit und funktionelle Ergebnisse ein Jahr nach partieller Aponeurektomie und Injektion von Kollagenase. *Handchirurgie Mikrochirurgie Plast Chir* 2013 ; 45 : 258-264.
87. **Wade R, Igali L, Figus A.** Skin involvement in Dupuytren's disease. *J Hand Surg Eur Vol* 2016 ; 41 : 600-608.
88. **Weinzweig N, Culver JE, Fleegler EJ.** Severe contractures of the proximal interphalangeal joint in Dupuytren's disease: combined fasciectomy with capsuloligamentous release versus fasciectomy alone. *Plast Reconstr Surg* 1996 ; 97 : 560-566.
89. **Zachariae L, Zachariae F.** Hydrocortisone acetate in the treatment of Dupuytren's contraction and allied conditions. *Acta Chir Scand* 1955 ; 109 : 421-31.
90. **Zemel NP, Balcomb T V, Stark HH, et al.** Dupuytren's disease in women: Evaluation of long-term results after operation. *J Hand Surg Am* 1987 ; 12 : 1012-1016.
91. **Zhou C, Hovius SER, Slijper HP, et al.** Predictors of Patient Satisfaction with Hand Function after Fasciectomy for Dupuytren's Contracture. *Plast Reconstr Surg* 2016 ; 138 : 649-655.
92. **Zhou C, Hovius SER, Slijper HP, et al.** Collagenase *Clostridium Histolyticum* versus Limited Fasciectomy for Dupuytren's Contracture: Outcomes from a Multicenter Propensity Score Matched Study. *Plast Reconstr Surg* 2015 ; 136 : 87-97.